Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Cancer patients
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Dear Editor, ancer patients are at increased risk for severe COVID-19 and have reduced humoral immune responses after SARS-CoV-2 infection and dual-dose BNT162b2 vaccination. Recently it was observed that a third dose of BNT162b2 is able to elicit higher SARS-CoV-2 anti-receptor-binding domain (RBD) IgG titers in solid-organ transplant patients and adults aged ≥60 years compared to two doses. Initial reports with limited sample size, also indicated that the a third BNT162b2 vaccination dose would be beneficial for solid tumor patients receiving active anti-neoplastic treatmentThe current study (B-VOICE: EudraCT 2021-000300-38), which is the first large-scale prospective study on humoral responses after a third dose six months post primo vaccination in cancer patients, confirms that most cancer patients will elicit a higher humoral response after a third dose of BNT162b2. Quantitative analysis of IgG-antibodies against the SARS-CoV-2 RBD antigen by enzyme-linked immunosorbent assay (ELISA) was performed before first dose, 28 days and six months after second dose and 28 days after third BNT162b2 dose in 141 oncohematological patients (Suppl. Table 1). From the 200 initial participants that were included in the B-VOICE study, 141 were evaluable after third dose. Drop-out was due to demise (20 participants, 10.0%), postponed vaccination due to illness or disease progression (8 participants, 4.0%), vaccination outside study protocol (5 participants, 2.5%) and consent withdrawal (26 participants, 13.0%).(...)
European Journal of Cancer , éditorial en libre accès, 2020